Monopolar versus bipolar transurethral resection of bladder Tumour: post-hoc analysis of a prospective trial
World Journal of Urology · 2024
DOI: 10.1007/s00345-024-05124-9 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift World Journal of Urology, 2024. Verfasst von Chris Ho-Ming Wong und 8 weiteren Autor:innen. Beteiligte Einrichtung: S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Cystectomy, Transurethral Resection of Bladder, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hong Kong Government.
Abstract (Originalsprache)
Introduction
Previously, in a randomised trial we demonstrated bipolar transurethral resection of bladder tumor (TURBT) could achieve a higher detrusor sampling rate than monopolar TURBT. We hereby report the long-term oncological outcomes following study intervention.
Methods
This is a post-hoc analysis of a randomized phase III trial comparing monopolar and bipolar TURBT. Only patients with pathology of non-muscle invasive bladder cancer (NMIBC) were included in the analysis. Per-patient analysis was performed. Primary outcome was recurrence-free survival (RFS). Secondary outcomes included progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS).
Results
From the initial trial, 160 cases were randomised to receive monopolar or bipolar TURBT. 24 cases of non-urothelial carcinoma, 22 cases of muscle-invasive bladder cancer, and 9 cases of recurrences were excluded. A total of 97 patients were included in the analysis, with 46 in the monopolar and 51 in the bipolar group. The median follow-up was 97.1 months. Loss-to-follow-up rate was 7.2%. Regarding the primary outcome of RFS, there was no significant difference (HR = 0.731; 95%CI = 0.433–1.236; P = 0.242) between the two groups. PFS (HR = 1.014; 95%CI = 0.511–2.012; P = 0.969), CSS (HR = 0.718; 95%CI = 0.219–2.352; P = 0.584) and OS (HR = 1.135; 95%CI = 0.564–2.283; P = 0.722) were also similar between the two groups. Multifocal tumours were the only factor that was associated with worse RFS.
Conclusion
Despite the superiority in detrusor sampling rate, bipolar TURBT was unable to confer long-term oncological benefits over monopolar TURBT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
- S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. jeremyteoh@surgery.cuhk.edu.hk.
- Department of Urology, Medical University of Vienna, Vienna, Austria. jeremyteoh@surgery.cuhk.edu.hk.
- Department of Surgery, Prince of Wales Hospital, 4/F, Clinical Sciences Building, New Territories, Hong Kong SAR, China. jeremyteoh@surgery.cuhk.edu.hk.
Förderung
- Hong Kong Government
Zitieren
APA
Wong, C. H., Lim, J. Y., Ko, I. C., Leung, D. K., Yuen, S. K., Yip, S. Y., Ng, C. F., Teoh, J. Y., & Chan, E. S. (2024). Monopolar versus bipolar transurethral resection of bladder Tumour: post-hoc analysis of a prospective trial. World Journal of Urology. https://doi.org/10.1007/s00345-024-05124-9
Vancouver
Wong CH, Lim JY, Ko IC, Leung DK, Yuen SK, Yip SY, et al. Monopolar versus bipolar transurethral resection of bladder Tumour: post-hoc analysis of a prospective trial. World Journal of Urology. 2024. doi:10.1007/s00345-024-05124-9
BibTeX
@article{Wong2024,
author = {Wong, Chris Ho-Ming and Lim, Joycelyn Yung-Yung and Ko, Ivan Ching-Ho and Leung, David Ka-Wai and Yuen, Steffi Kar-Kei and Yip, Siu-Ying and Ng, Chi-Fai and Teoh, Jeremy Yuen-Chun and Chan, Eddie Shu-Yin},
title = {Monopolar versus bipolar transurethral resection of bladder Tumour: post-hoc analysis of a prospective trial},
journal = {World Journal of Urology},
year = {2024},
doi = {10.1007/s00345-024-05124-9}
}
EUVIMED